TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23642372
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser photocoagulation (L)
Study: 23642372
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser photocoagulation plus intravitreal triamcinolone (L+T)
Study: 21346758
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of oral deuterated alfentanil and intravenous unlabeled alfentanil
Study: 21346758
Drug: Sequential dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential dosing of alfentanil
Study: 21346758
Drug: Simultaneous dosing
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous dosing of alfentanil
Study: 21346758
Drug: Rifampin, ketoconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin, ketoconazole, and grapefruit juice (as inducers/inhibitors)
Study: 19451297
Drug: Lopinavir-ritonavir (LPV/r)
Normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (LPV/r) monotherapy
Study: 19451297
Drug: Lopinavir-ritonavir (LPV/r)
Normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (LPV/r) plus zidovudine and lamivudine triple therapy
Study: 1563557
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of highly viscous prostaglandin E2 (PGE2) gel
Study: 3907288
Drug: Toluene exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene exposure (382 mg/m3 for 6 1/2 hours)
Study: 29146657
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy, diet and exercise for 12 months
Study: 17156651
Drug: niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER 500 mg/d for 4 weeks and then 1000 mg/d for 4 weeks
Study: 17156651
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg/d for 8 weeks
Study: 17156651
Drug: atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin (10 mg/d) plus niacin ER (starting from 500 mg/d to 1000 mg/d after 4 weeks) for 8 weeks
Study: 1401694
Drug: Nandrolone 2
Normalized name: nandrolone 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone 2 mg/kg
Study: 3908352
Drug: Naltrexone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (200 mg daily)
Study: 27242010
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene with sterile water (SG)
Study: 29900909
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (scaling and root planning)
Study: 21259024
Drug: CHO-PRO (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO (18 g L(‐1) PRO, 72 g L(‐1) CHO)
Study: 21259024
Drug: PLA (76
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (76 g L(‐1) CHO)
Study: 19038426
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy‐Prostate scores
Study: 11589384
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of physiological dose of PYY
Study: 7651811
Drug: Uppercase consonant
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uppercase consonant trigrams (e.g., FMH) as primes
Study: 320951
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) and FT‐207 at the same dose schedule
Study: 21268722
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rt-PA) (1 mg in each lumen) once weekly
Study: 21268722
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 U per milliliter) three times per week
Study: 17509249
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment for MS symptoms
Study: 17509249
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for MS symptoms
Study: 9277416
Drug: Low-dose atropine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atropine (5 micrograms.kg‐.h‐1)
Study: 9277416
Drug: CCK‐A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐A receptor antagonist loxiglumide (22 mumol.kg‐.h‐1)
Study: 19049556
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CoQ(10)/vitamin E therapy
Study: 19049556
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CoQ(10)/vitamin E therapy
Study: 11083192
Drug: Adenosine-exercise (treadmill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine-exercise (treadmill exercise during adenosine infusion)
Study: 11083192
Drug: Adenosine-nonexercise (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine-nonexercise (adenosine infusion alone)
Study: 9193193
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of d,l-fenfluramine hydrochloride (Pondimin)
Study: 8064072
Drug: Nedocromil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (4 mg)
Study: 8626987
Drug: Furosemide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (30 mg)
Study: 8064072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nedocromil and furosemide
Study: 433806
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g nitrogen diet
Study: 1163469
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g nitrogen diet
Study: 1163469
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement of 0.9 g on the 12 g nitrogen diet
Study: 1163469
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g nitrogen diet
Study: 21327728
Drug: Transtympanic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic steroid injections (Group A)
Study: 21327728
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of steroids (Group B)
Study: 16489524
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (very-point technique)
Study: 15355582
Drug: Psychodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic therapy
Study: 10647539
Drug: DRINK (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRINK (oral rehydration, 0.45% NaCl)
Study: 10647539
Drug: IV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (intravenous rehydration, 0.45% NaCl)
Study: 7537488
Drug: Alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 2.5 mg tid
Study: 7537488
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens 160 mg bid
Study: 1963273
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) at 55 mg/m2, Etoposide at 100 mg/m2 (days 1-3), Vincristine at 2 mg (day 1)
Study: 1963273
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) at 60 mg/m2
Study: 1963273
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) at 40 mg/m2, 50 mg/m2, and 55 mg/m2
Study: 1963273
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) at 55 mg/m2
Study: 14686965
Drug: Acarbose, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose, 150 mg/day
Study: 11829107
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) at a daily dose of 60 mg
Study: 776487
Drug: Atenolol 75
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 75 mg/day, increased to a maximum of 900 mg if tolerated
Study: 776487
Drug: Atenolol therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol therapy after 8 weeks
Study: 28643825
Drug: Implant-supported removable
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported removable partial denture with implants placed in the molar region
Study: 28643825
Drug: Implant-supported removable
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported removable partial denture with implants placed in the pre-molar region
Study: 21574446
Drug: Cytoflavin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin as a component of combined therapy
Study: 16952987
Drug: Anti-TNF-alpha therapy
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-alpha therapy
Study: 11275039
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (3 million IU daily for 5 days, followed by 2 days of rest for 3 weeks)
Study: 8292640
Drug: Experimental condition:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental condition: one monthly non‐random urine screen, one monthly counseling session, one monthly doctor visit, two times per month methadone pick up, a quarterly true random urine screen and participation in a diversion control program
Study: 2949920
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin (0.30 U/kg)
Study: 2949920
Drug: Porcine ultralente
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine ultralente insulin (0.30 U/kg)
Study: 2949920
Drug: Bovine ultralente
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine ultralente insulin (0.30 U/kg)
Study: 26362831
Drug: Valsartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (angiotensin receptor blocker)
Study: 12904684
Drug: Amlodipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (calcium channel blocker)
Study: 17559152
Drug: PEGIFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day + EPO 40,000 U/week
Study: 17559152
Drug: PEGIFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day
Study: 17559152
Drug: PEGIFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGIFN alpha‐2b + higher dose WBR 15.2 mg/kg/day + EPO
Study: 28939589
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who had never used hormone therapy
Study: 25386711
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron treatment (500 mg)
Study: 20844049
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) therapy
Study: 11784431
Drug: Sulfadoxine-pyrimethamine (Fansidar)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (Fansidar) as replacement therapy
Study: 56146
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 500 ml during surgery and on the following three days
Study: 56146
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution 500 ml during surgery and on the following three days
Study: 3276390
Drug: Chemotherapy arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy arms
Study: 18569274
Drug: Silica gel
Normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silica gel
Study: 28291842
Drug: Opioid remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid remifentanil (0.15 μg/kg/min) administered intravenously for 60 minutes
Study: 15126714
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g x kg NaHCO3
Study: 15126714
Drug: 0.207 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.207 g x kg NaCl (CON)
Study: 8160720
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium fiber (6.7 g daily)
Study: 29948956
Drug: Pyridoxine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (60 mg per day)
Study: 18471512
Drug: Terlipressin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1-2 mg/4 hour, intravenously) and albumin (1 g/kg followed by 20-40 g/day)
Study: 12921475
Drug: SLI381 (Adderall
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 (Adderall XR) 10 mg
Study: 12921475
Drug: SLI381 (Adderall
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 (Adderall XR) 20 mg
Study: 12921475
Drug: SLI381 (Adderall
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 (Adderall XR) 30 mg
Study: 12921475
Drug: Adderall 10
Normalized name: Adderall 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall 10 mg (active control)
Study: 9044877
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg and 160 mg)
Study: 3899554
Drug: Postprandial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial exercise preceded by the usual dose of insulin
Study: 3899554
Drug: Postprandial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial exercise preceded by one-half of the usual dose of insulin
Study: 3899554
Drug: Postprandial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial exercise preceded by two-thirds of the usual dose of insulin
Study: 3899554
Drug: Postprandial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial exercise without the usual dose of insulin
Study: 2929911
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg
Study: 12196659
Drug: Oral albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral albuterol for 6 months
Study: 10503860
Drug: GM-CSF mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthrinse (0.5 microg/mL), administered for 1 minute 3 times per day after oral hygiene procedures, starting from the first day of mucositis until clinical improvement.
Study: 10503860
Drug: GM-CSF mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthrinse (0.5 microg/mL).
Study: 1914267
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of sublingual nitroglycerin without transdermal nitroglycerin (Group 1)
Study: 1914267
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of sublingual nitroglycerin with 12-hour-daily intermittent therapy of transdermal nitroglycerin (Group 2)
Study: 1914267
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 3)
Study: 1914267
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 4)
Study: 31524642
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (neoadjuvant)
Study: 31524642
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TRG and TNM
Study: 24980290
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVOO, 10 g)
Study: 24980290
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (10 g)
Study: 2110386
Drug: Ifosfamide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (8 to 10 g/m2) with mesna uroprotection, bolus administration
Study: 2110386
Drug: Ifosfamide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (8 to 18 g/m2) with mesna uroprotection, continuous infusion
Study: 2110386
Drug: Ifosfamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (up to 18 g/m2)
Study: 2110386
Drug: Ifosfamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (16 g/m2)
Study: 2110386
Drug: Ifosfamide (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (18 g/m2)
Study: 347992
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate intranasal aerosol
Study: 31179799
Drug: Standard infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infusion puncture method (Control)
Study: 28591198
Drug: Single 45mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 45mg dose of primaquine (equivalent to three SLD PQ)
Study: 28591198
Drug: Single 45mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 45mg dose of primaquine
Study: 26202995
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli (1 lozenge containing Lactobacillus reuteri DSM 17938 and ATCC PTA 5289, twice daily for 12 weeks)
Study: 26202995
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 12 weeks)
Study: 19388893
Drug: Midazolam (0.05-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05-0.1 mg/kg orally)
Study: 16455894
Drug: alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha interferon 2b (IFN-alpha2b) (3 million units three times a week) + ribavirin (800 mg/day)
Study: 16455894
Drug: pegylated IFN-alpha2b
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated IFN-alpha2b (1.5 mug/kg of body weight/week) + ribavirin (800 mg/day)
Study: 16455894
Drug: HCV CA
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV CA below the threshold value (4.18 log(10) pg/ml . 10(4))
Study: 8607321
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg.kg‐1)
Study: 30448246
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone (TAC) injections
Study: 27906839
Drug: Bosentan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (500 mg)
Study: 26041745
Drug: AC→XT (Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC→XT (Capecitabine 825 mg/m² twice daily, days 1‐14; Docetaxel 75 mg/m² on day 1)
Study: 26041745
Drug: AC→T (Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC→T (Doxorubicin and Cyclophosphamide followed by Docetaxel, T dose: 100 mg/m² on day 1)
Study: 23377341
Drug: Ketoconazole foam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole foam, 2%, twice daily
Study: 16113459
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (duration: 8 weeks)
Study: 16113459
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (duration: 4 years)
Study: 16113459
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (population: adults with asthma)
Study: 11497388
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NK1 receptor antagonists with existing agents
Study: 29324705
Drug: Chitosan treatment
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan treatment (3200 mg daily)
Study: 17377389
Drug: 0.1% retinaldehyde/6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% retinaldehyde/6% glycolic acid cream (RALGA)
Study: 17935515
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (control)
Study: 9507234
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g highly purified ethyl esters of eicosapentaenoic acid (EPA) (95% pure)
Study: 9507234
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g docosahexaenoic acid (DHA) (90% pure)
Study: 1254157
Drug: Post-operative prophylactic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative prophylactic chemotherapy
Study: 1254157
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy for at least 2 years
Study: 30692875
Drug: High-Dose Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Remifentanil
Study: 30692875
Drug: Low-Dose Remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Remifentanil